VENLAFAXINE VIATRIS LP 37.5 mg, extended-release capsule 30 capsules, CIP 3400930189757
Active ingredients: Venlafaxine hydrochloride, Venlafaxine
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Extended-release capsule30 capsules, CIP 3400930189757orale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- VENLAFAXINE VIATRIS LP 37,5 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) PVC polyéthylène PVDC aluminium de 1 gélule(s)
- Marketing authorisation holder
- VIATRIS SANTE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 29 Nov 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64860361CIP73018975CIP133400930189757Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE VENLAFAXINEgélule | 42,43 mg · une gélule | SA |
| VENLAFAXINEgélule | 37,5 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.